We have a special Dietary Therapies section on our website and more specificially, a monthly series of articles written by or assigned through Eric Kossoff, MD. Last month Dr. Kossoff had two articles published. We present here on epilepsy.com the...
On March 13, 2008, “The Epilepsy Pipeline Conference: Portal into CNS Opportunity” will be held in San Francisco. Sponsored by the Epilepsy Therapy Project (ETP), the day-long meeting will focus on drug development strategies, investing, and...
Steven C. Schachter, MD, received a special honor in India when he delivered the 28th T.S. Srinivasan Endowment Oration in Chennai on “Brainstorms Village-Meeting the Challenge of Disabling Epilepsy.” Quoted in India’s national newspaper, The...
When a Food and Drug Administration (FDA) alert was issued regarding antiepileptic drugs and suicidality, epilepsy.com responded with a Breaking News story and several articles to help patients put the findings in context. FDA Alert , 3 articles...
It was announced on February 27, 2008 that the U.S. Food and Drug Administration (FDA) has accepted Ovation Pharmaceuticals’ new drug applications (NDA) for Sabril® (vigabatrin) in two types of epilepsies. The FDA assigned a priority NDA review for...

Pages